SPON2 and metastatic malignant neoplasm in the lymph nodes: Our results showed that the following prognostic markers were associated with poor overall survival: differentiation (hazard ratio [HR], 0.743; 95% confidence interval [CI]: 0.578–0.955; P =.020), lymph node metastasis (HR, 0.358; 95%CI: 0.198–0.648; P =.001), clinical stage (pTNM stage III–IV; HR, 1.170; 95%CI: 0.921–1.486; P =.032), pattern (HR, 1.143; 95%CI: 0.986–1.325; P =.026), and higher SPON2 expression (HR, 1.583; 95%CI: 1.035–2.421; P =.034) (Table 2).